Newly diagnosed hypertension pt with 150/90 after 3 readings give a treatment plan
Reading File
Finding Sources
Searching PubMed
"hypertension" AND "treatment guidelines"
Searching the Web
2025 hypertension treatment guidelines stage 1 first line therapy JNC ACC AHA
Finding Sources
Reading Web Page
https://cdn.ymaws.com/www.oshp.net/resource/resmgr/2025_fall…
Finding Sources
Finding Sources
Reading File
Reading File
I now have excellent data from both textbooks and the 2025 ACC/AHA guidelines. Let me compose a comprehensive treatment plan.
Hypertension Treatment Plan - BP 150/90 mmHg (3 confirmed readings)
Classification
A BP of 150/90 mmHg confirmed on 3 separate readings = Stage 2 Hypertension (SBP ≥ 140 mmHg) per 2025 ACC/AHA guidelines. This is above the Stage 1 threshold (130-139/80-89) and requires prompt pharmacologic therapy alongside lifestyle modification - do not delay treatment with lifestyle-only for 3-6 months as you would for lower-risk Stage 1.
Step 1: Initial Workup Before or at Diagnosis
Before finalizing therapy, establish baseline and rule out secondary causes:
| Test | Purpose |
|---|---|
| Basic metabolic panel (BMP) | Renal function, electrolytes, glucose |
| Urinalysis with spot albumin-to-creatinine ratio | Renal target organ damage |
| Lipid panel | Cardiovascular risk |
| ECG | Left ventricular hypertrophy, arrhythmia |
| Fasting glucose / HbA1c | Diabetes comorbidity |
| CBC | Anemia, secondary causes |
| Thyroid (TSH) if clinically indicated | Hypothyroid-related HTN |
| Aldosterone/renin ratio | Screen for primary aldosteronism if stage 2 (new 2025 guideline recommendation) |
Calculate 10-year CVD risk using the AHA PREVENT calculator - this guides treatment intensity.
Step 2: Lifestyle Modifications (Begin Immediately - Non-Negotiable)
These are foundational and must accompany any drug therapy:
| Intervention | Target | Expected BP Reduction |
|---|---|---|
| Dietary sodium restriction | < 2.3 g/day (ideally < 1.5 g/day) | 2-8 mmHg |
| DASH diet | Fruits, vegetables, low-fat dairy, reduce saturated fat | 8-14 mmHg |
| Weight loss | 1 mmHg per kg lost | Variable |
| Aerobic exercise | 150 min/week moderate-intensity | 4-9 mmHg |
| Alcohol reduction | ≤ 1 drink/day women, ≤ 2/day men | 2-4 mmHg |
| Potassium-based salt substitutes | Use at home (avoid in CKD or on K-sparing drugs) | 2-5 mmHg |
| Smoking cessation | Complete cessation | Reduces overall CV risk |
Step 3: Pharmacologic Therapy
When to Start Drugs
At 150/90 (Stage 2), start drug therapy immediately - do not wait. Per 2025 ACC/AHA guidelines, Stage 2 hypertension warrants initiation of two first-line agents from different classes simultaneously (Class I recommendation), ideally as a single-pill combination (SPC) to improve adherence.
First-Line Drug Classes (Race-neutral per 2025 guidelines)
| Class | Examples | Notes |
|---|---|---|
| Thiazide/thiazide-like diuretics | Chlorthalidone 12.5-25 mg daily; HCTZ 12.5-25 mg daily | Chlorthalidone preferred over HCTZ for superior CV outcomes |
| ACE inhibitors | Lisinopril 10-40 mg daily; Ramipril 5-10 mg daily | Avoid in bilateral RAS, pregnancy; monitor K+ and Cr |
| Angiotensin receptor blockers (ARBs) | Losartan 50-100 mg daily; Olmesartan 20-40 mg daily | Use if ACEi-intolerant (cough); avoid combining with ACEi |
| Dihydropyridine CCBs | Amlodipine 5-10 mg daily; Nifedipine ER 30-60 mg daily | Good for elderly, ISH, and Black patients |
Do NOT combine an ACEi + ARB (Class III Harm per 2025 ACC/AHA - increased adverse renal events without added BP benefit).
Recommended Starting Combination for 150/90
Option 1 (preferred): ACEi + CCB (e.g., lisinopril 10 mg + amlodipine 5 mg)
- Supported by ACCOMPLISH trial; reduces cardiovascular events vs ACEi + thiazide
Option 2: ACEi + thiazide (e.g., lisinopril 10 mg + chlorthalidone 12.5 mg)
- Well-established, cost-effective
Option 3: ARB + CCB or ARB + thiazide (for ACEi-intolerant patients)
Step 4: Comorbidity-Driven Drug Selection
Adjust first-line choice based on concurrent conditions:
| Comorbidity | Preferred Drug(s) |
|---|---|
| Diabetes | All first-line classes effective; ACEi/ARB if albuminuria present |
| CKD with proteinuria | ACEi or ARB (1st line); target < 130/80 |
| Heart failure with reduced EF | ACEi/ARB + beta-blocker + diuretic |
| Post-MI / CAD | Beta-blocker + ACEi/ARB |
| Atrial fibrillation | Beta-blocker or non-DHP CCB (diltiazem/verapamil) |
| Asthma/COPD | Avoid beta-blockers; prefer CCB or ACEi/ARB |
| Black patients (no CKD/DM) | Thiazide + DHP CCB preferred (ACEi/ARB less effective as monotherapy in this group) |
| Older adults (>65) | Start low, go slow; DHP CCBs or thiazides often well-tolerated |
| Gout | Avoid thiazides; prefer losartan (uricosuric effect) |
Step 5: BP Target
Universal target: < 130/80 mmHg (2025 ACC/AHA, applies to most patients)
Individualized exceptions:
- Institutionalized/frail elderly: may accept < 140/90
- CKD with albuminuria: < 130/80 strongly recommended
- Pregnancy: < 140/90 (use labetalol or nifedipine ER; avoid ACEi/ARB)
Step 6: Resistant or Uncontrolled HTN - Escalation
If BP remains above goal after 3 full-dose first-line agents:
- Add spironolactone 25-50 mg/day (best fourth agent per PATHWAY-2 trial)
- Screen for secondary causes: primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma, Cushing's
- Consider renal denervation as an adjunctive option (new in 2025 guidelines for select resistant patients)
- Refer to hypertension specialist
Step 7: Follow-up Schedule
| Timeframe | Action |
|---|---|
| 2-4 weeks after initiating therapy | Recheck BP, assess side effects, check BMP (K+, Cr) |
| Monthly until at goal | Titrate doses as needed |
| Every 3-6 months at goal | Routine monitoring |
| Annually | Repeat labs, reassess CVD risk, screen for target organ damage |
Summary Algorithm for This Patient (150/90, No Known Comorbidities)
BP 150/90 x3 readings
|
├── Workup: BMP, UA, lipids, ECG, aldosterone/renin
├── Calculate PREVENT 10-yr CVD risk
|
├── START TODAY:
| - Lifestyle modifications (DASH, sodium restriction, exercise)
| - Two first-line drugs simultaneously (e.g., lisinopril 10mg + amlodipine 5mg)
|
├── Follow-up in 2-4 weeks
| - If BP controlled: maintain, recheck BMP
| - If not controlled: titrate doses upward
|
├── If still not at goal on 2 maxed agents:
| - Add chlorthalidone 12.5-25mg
|
└── Goal: BP < 130/80 mmHg
Key 2025 Guideline Updates (vs 2017): Use PREVENT calculator for risk; screen for primary aldosteronism in all Stage 2 patients; race-neutral drug selection; potassium-based salt substitutes now recommended; renal denervation is now an option for resistant HTN. Source: 2025 ACC/AHA Hypertension Guidelines (Circulation. 2025;152:1-105).
Textbook sources: - Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 715-716 | - Lippincott Illustrated Reviews Pharmacology, 16e, p. 293
This is a shared conversation. Sign in to Orris to start your own chat.